Pharmaceuticals

Tumor Models Sector Forecast Shows Robust Momentum, Climbing to $3.57 Billion With 10.8% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the tumor models market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Tumor Models Market show for the 2026–2030 period?

The tumor models market has seen rapid expansion in recent years. It is projected to increase from $2.13 billion in 2025 to $2.37 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.3%. Historically, this growth can be ascribed to factors such as the limited availability of advanced tumor models, the reliance on traditional 2D cell cultures, growing cancer research funding, the increasing prevalence of cancer, and the adoption of orthotopic and heterotopic models.

The tumor models market is anticipated to experience significant expansion in the coming years. This market is projected to reach $3.57 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.8%. Several factors contribute to this growth during the forecast period, including advancements in organ-on-a-chip and 3D spheroid technologies, a heightened emphasis on personalized oncology treatments, the expanding role of contract research organizations (CROs) in tumor research, increased pharmaceutical R&D spending, and the incorporation of AI and big data analytics into tumor model investigations. Key trends anticipated during this period involve a greater adoption of 3D tumor spheroids and organ-on-a-chip models, an escalating need for personalized medicine and targeted cancer therapies, the broadening application of xenograft and genetically engineered mouse models (GEMMs), an increase in drug discovery and toxicology studies employing tumor models, and enhanced collaborations between pharmaceutical firms and academic bodies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27441&type=smp

What Drivers Are Shaping The Development Of The Tumor Models Market?

The increasing need for customized medicine is anticipated to fuel the expansion of the tumor models market in the future. Customized medicine describes a healthcare approach that leverages details regarding an individual’s genetic makeup and daily habits to develop treatments and care plans uniquely suited to them. The emergence of personalized medicine stems from individuals favoring health solutions that provide real-time surveillance and therapeutic strategies tailored to their distinct biological profiles. Tumor models assist personalized medicine by serving as experimental platforms that replicate the characteristics of actual human cancers, thereby enabling scientists and doctors to evaluate and forecast the response of individual patient tumors to particular therapies, facilitating a more customized therapeutic strategy. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a US based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) sanctioned 26 new personalized medicines in 2023, which marked a considerable rise from the 12 approved in 2022. Consequently, the escalating requirement for personalized medicine is propelling the development of the tumor models market.

Which Segments Are Contributing To The Growth Of The Tumor Models Market?

The tumor models market covered in this report is segmented –

1) By Type Of Tumor: Primary Tumor Models, Metastatic Tumor Models, Orthotopic Tumor Models, Heterotopic Tumor Models

2) By Application: Drug Discovery And Development, Cancer Research, Personalized Medicine, Toxicology Studies

3) By Technology: Xenograft Models, Genetically Engineered Mouse Models (GEMMs), Three-Dimensional (3D) Tumor Spheroids, Organ-On-A-Chip Models

4) By End-User: Pharmaceutical And Biotechnology Companies, Academic Institutions, Contract Research Organizations (CROs), Government Research Organizations

Subsegments:

1) By Primary Tumor Models: Carcinoma Models, Sarcoma Models, Glioma Models, Melanoma Models, Leukemia Models, Lymphoma Models

2) By Metastatic Tumor Models: Lung Metastasis Models, Bone Metastasis Models, Liver Metastasis Models, Brain Metastasis Models, Lymph Node Metastasis Models

3) By Orthotopic Tumor Models: Orthotopic Breast Cancer Models, Orthotopic Lung Cancer Models, Orthotopic Pancreatic Cancer Models, Orthotopic Colon Cancer Models, Orthotopic Prostate Cancer Models

4) By Heterotopic Tumor Models: Subcutaneous Tumor Models, Intramuscular Tumor Models, Intraperitoneal Tumor Models

What Trends Are Expected To Impact The Competitive Landscape Of The Tumor Models Market?

Leading companies in the tumor models market are prioritizing the creation of advanced solutions, such as tumor spheroid models, to improve the physiological relevance and forecasting accuracy of in vitro cancer models. Tumor spheroid models are characterized as three-dimensional (3D) clusters of cancer cells that naturally develop into spherical configurations in culture. As an example, in June 2024, Predictive Oncology, a US-based provider of sophisticated 3D cell culture technologies and predictive oncology solutions, unveiled new 3D cell technology to speed up the discovery of cancer therapeutic drugs. This technology features unique capabilities including advanced 3D tumor spheroid and organoid models that closely simulate the tumor microenvironment, high-throughput screening for quick drug assessment, support for patient-derived personalized tumor models, comprehensive analysis of drug penetration in 3D structures, and integration with AI-driven data analytics to enhance predictive accuracy and provide deeper insights into therapeutic responses.

Who Are The Major Companies Operating In The Tumor Models Market?

Major companies operating in the tumor models market are WuXi AppTec Co Ltd., Charles River Laboratories International Inc., Pharmaron Beijing Co. Ltd., The Jackson Laboratory, Taconic Biosciences Inc., Cyagen Biosciences Inc., Crown Bioscience Inc., Champions Oncology Inc., InSphero AG, Creative Biolabs Inc., Oncodesign S.A., Xentech S.A., MIMETAS BV, Experimental Pharmacology and Oncology Berlin-Buch GmbH.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/tumor-models-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Tumor Models Market?

North America was the largest region in the tumor models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Tumor Models Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27441&type=smp

Browse Through More Reports Similar to the Global Tumor Models Market 2026, By The Business Research Company

Voice Payment Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/voice-payment-software-global-market-report

Voice Banking Market Report 2026

https://www.thebusinessresearchcompany.com/report/voice-banking-global-market-report

Voice Commerce Market Report 2026

https://www.thebusinessresearchcompany.com/report/voice-commerce-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795